ATTY DOCKET NO.

9516-335-999 (501872-999496) APPLICATION NO. 10/590,575

LIST OFFREFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT: Zeldis FILING DATE

GROUP August 22, 2006 1617

HANDY OF TRACE		<i>#</i>			FILING DATE		GROUP	
TRAD	TIAME	·			August 22, 2006		1617	
MAD	EM		U.S. PA	ATENT DOCUM	ENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	N/	ME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	A01	60/607,408		Muller et al.				9/3/04
	A02	60/454,149		Man et al.				3/12/03
	A03	60/452,460		Muller et al.				3/5/03
	A04	60/452,374		Zeldis et al.				3/6/03
	A05	60/438,450		Muller et al.		_		1/7/03
	A06	60/438,448		Muller et al.				1/7/03
	A07	10/934,974		Muller et al.				9/3/04
	A08	10/900,332		Muller et al.				7/28/04
	A09	10/900,270		Muller et al.				7/28/04
	A10	10/798,372		Man et al.				3/12/04
	All	10/798,317		Man et al.				3/12/04
	A12	10/794,931		Muller et al.				3/5/04
	A13	10/748,085		Man et al.				12/29/03
	A14	2004/0167199	8/26/04	Muller et al.				
	A19	20030187052	10/2/03	Muller et al.				
	A18	6,699,899	3/2/04	Man et al.				
	A17	6,667,316	12/23/03	Man et al.				
	A18	6,046,221	2/11/03	Muller et al.				
	A19	6,479,554	11/12/02	Muller et al.				
	A20	6,429,221	8/6/02	Muller et al.				
	A21	6,326,388	12/4/01	Man et al.				
	A22	6,284,780	9/4/01	Muller et al.				
	A23	6,262,101	7/17/01	Muller et al.				
	A23	6,214,857	4/10/01	Muller et al.				
	A25	6,200,987	3/13/01	Muller				
	A20	6,180,644	1/30/01	Muller et al.				
	A27	6,130,226	10/10/00	Muller et al.				
	A22	6,075,041	6/13/00	Muller				
	A29	6,046,221	4/4/00	Muller et al.				
	A30	6,020,358	2/1/00	Muller et al.				
	A31	6,011,050	1/4/00	Muller et al.				
	A32	5,968,945	10/19/99	Muller et al.				
	A33	5,929,117	7/27/99	Muller et al.				
	A34	5,877,200	3/2/99	Muller				
	A35	5,801,195	9/1/98	Muller et al.				
	A36	5,736,570	4/7/98	Muller et al.				

					ATTY DOCKET NO.	APPLICATION NO.	
LICTO	c necei	PENCES SITED DA	A DDI ICA	NE	9516-335-999 (501872-999496)	10/590,575	
LIST OF	r KEFE	RENCES CITED BY (Use several sheets if n		N I APPLICANT:			
		(	,		Zeldis		
					FILING DATE	GROUP	
					August 22, 2006	1617	
	A37	5,728,845	3/17/98	Muller et al.			
,	A38	5,728,844	3/17/98	Muller et al.	5170		
	A39	5,703,098	12/30/97	Muller et al.			
	A40	5,698,579	12/16/97	Muller			
	A41	5,658,940	8/19/97	Muller et al.			
	A42	5,605,914	2/25/97	Muller			
	A43	5,463,063	10/31/95	Muller			
	A44	5,134,127	7/28/92	Stella et al.			
	A45	2003/0185826	10/2/03	Tobinick			
	A46	2003/0113318	6/19/03	Tobinick			
	A47	2003/0049256	3/13/03	Tobinick			
	A48	2003/0007972	1/9/03	Tobinick			
	A48	2002/0131955	9/19/02	Tobinick			
	A50	2002/0131954	9/19/02	Tobinick			
	A51	2002/0054899	5/9/02	Zeldis			
	A52	2001/0026801	10/4/01	Tobinick			
	A51	2001/0016195	8/23/01	Tobinick			
_	A54	2001/0004456	6/21/01	Tobinick			
	A55	6,623,736	9/23/03	Tobinick			
	A58	6,537,549	3/25/03	Tobinick			
	A57	6,471,961	10/29/02	Tobinick			
	A58	6,428,787	8/6/02	Tobinick			
	A52	6,423,321	7/23/02	Tobinick			
	A64	6,419,944	7/16/02	Tobinick			
	A61	6,419,934	7/16/02	Tobinick			
	A67	6,379,666	4/30/02	Tobinick			
ri .	A64	6,297,286	10/2/01	Huckle			
	A64	6,177,077	1/23/01	Tobinick			
	A65	6,015,557	1/18/00	Tobinick et al.			
	A64	5,929,117	7/27/99	Muller et al.			
	A67	5,877,200	3/2/99	Muller			
	A64	5,739,119	4/14/98	Galli et al.			
	A69	5,698,579	12/16/97	Muller			
	A70	5,434,170	7/18/95	Andrulis			

		FOREIGN	PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
B01	WO 03/080048	10/2/03	PCT				
B02	WO 03/080049	10/2/03	PCT				

	-		
Sheet	1	OT.	4

<u> </u>					Sheet 3 01
	B03	WO 01/45702	6/28/01	PCT	
	B04	WO 01/34606	·5/17/01`	PCT	
	B05	WO 99/06041	2/11/99	PCT	
	B06	WO 97/23457	7/3/97	PCT	
	B07	WO 97/08143	3/6/97	PCT	
	B08	WO 95/01348	1/12/95	PCT	

Col. Akaike et al., 1993, "Nolingme enhances the development of voltage-dependent Ca2+ current and serotonin-induced current in rat pheochromocytoma cells," Brain Res. 620(1):58-63  Col. Aluuke et al., 2002, "Chaperone suppression of alpha-synutoein toxicity in a Drosophila model for Parkinson's disease," Science 295(5559):865-888  Col. Blancher et al., 1989, "Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease," Brain Res. 477(1-2):90-99  Banta et al., 1977, "Elevated manganese levels associated with dementia and extrapyramidal signs," Neurology 27(0):219-219  Col. Bounthouladze et al., 2003, "A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by tribibitors of phosphodeisetrase 4," Prior. Natl Acad. Sci. USA 10(18):10518-10522  Col. Col. Col. Res. 1, 1987, "Familial Parkinson's disease; possible role of environmental factors," Can. J. Neurol. Sci. Caracresi et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with tevedopa: role of early treatment and disease progression," Neurology 41(3):380-384  Col. Caracresi et al., 1993, "Therapeutic use of a selective AcMP phosphodiestress einhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334  Cl. Cherry et al., 1999, "Therapeutic use of a selective AcMP phosphodiestress einhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334  Cl. Cherry et al., 1999, "Therapeutic use of a selective AcMP phosphodiestress einhibitor (Rolipram) in Parkinson's disease, "Pharmacol. Res. Commun. 15(3):329-334  Cl. Cherry et al., 1999, "Therapeutic use of a selective AcMP phosphodiestress einhibitor (Rolipram) in Parkinson's disease, "Pharmacol. Res. Commun. 15(3):329-334  Cl. Corral et al., 1999, "Therapeutic use of a selective AcMP phosphodiestress einhibitor (Rolipram) in Parkinson's disease, "Pharmacol. Res. Commun. 15(3):329-334  Cl. Corral et al., 1999, "Therapeutic use of a selective A							
continued current in rat pheochromocytoma cells, "Brain Res. 620(1):58-63.  Qualtuck et al., 2002, "Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease," Science 295(556):865-868  Bancher et al., 1989, "Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary targles in Atzheimer's disease," Brain Res. 477(1-2):90-99  Danta et al., 1997, "Elevated manganese levels associated with dementia and extrapyramidal signs," Neurology 27(3):213-216  Daraitser, 1990, The Genetics of Neurological Disorders, 2"d ed., pp. 85-88  Bourichouladze et al., 2003, "A mouse model of Rubinstein-Tayls syndrome defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4," Proc. Natl. Acad. Sci. USA 100(18):10518-10522  Corline et al., 1987, "Familial Parkinson's disease; possible role of environmental factors," Can. J. Neurol. Sci. 14(3):303-305  Cos. Caraceni et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with levodops, role of early treatment and disease progression," Neurology 41(3):380-384  Cop. Casacchia et al., 1993, "Therapeutic use of a selective CAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334  Col. Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect," J. Gorny. Neurol. 407(2):287-301  Corl Corral et al., 1999, "Immunomodulation by thallidomide and thallidomide analogues," Ann. Rheum. Dis. 58(Suppl. 1):1107-1113  Corl Corporer et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80  Corl Signa, "Parkinson's Color Neurol. 407(2):287-301  Corl Giroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  Corl Giroy et al., 1979, "Medical Neurology, MacMillan Publishing Co., pp. 175-179  Corl Giroy et al., 1979, "Neurology of the Color of Acetybrolinesterase determinations by the M	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)						
disease, "Science 295(556):865-868 Bancher et al., 1998, "Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tagles in Atzheimer's disease," Brain Res. 477(1-2):90-99 Banta et al., 1997, "Elevated manganese levels associated with dementia and extrapyramidal signs," Neurology 27(3):213-216 C05 Baraitser, 1990, The Genetics of Neurological Disorders, 2" ed., pp. 85-88 Bourtchouladze et al., 2003, "A mouse model of Rubinstein-Tayls syndrome defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4," Proc. Natl. Acad. Sci. USA 100(18):10518-10522 C07 Calne et al., 1987, "Familial Parkinson's disease: possible role of environmental factors," Can. J. Neurol. Sci. 14(3):303-305 C08 Caraceni et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa. role of early treatment and disease progression," Neurology 41(3):340-344 C09 Casacchia et al., 1993, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334 C10 Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect," J. Comp. Neurol. 407(2):287-301 C11 Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl. 1):1107-1113 C12 Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80 C13 Crook et al., 1989, "The choinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurp. Psychiatry 66(2):137-147 C15 Free et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivastimine," Soc. Neurosurp. 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 1974, 197	(	C01	induced current in rat pheochromocytoma cells," Brain Res. 620(1):58-63				
coal Banta et al., 1977, "Elevated manganese levels associated with dementia and extrapyramidal signs," Neurology 27(3):213-216  Cob Baraiters (1990, The Genetics of Neurological Disorders, 2"d ed., pp. 85-88  Cob Bount-houladze et al., 2003, "A mouse model of Rubinstein-Tayb) syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4," Proc. Natl. Acad. Sci. USA 100(18):10318-10522  Corne et al., 1987, "Familial Parkinson's disease; possible role of environmental factors," Can. J. Neurol. Sci. 14(3):303-304  Coracent et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with levedops. Tole of early treatment and disease progression," Neurology 41(3):380-384  Corne et al., 1998, "The repeated use of a selective AMP phosphodiesterase inhibitor (Rolipram) in Parkinsonian patients treated long term with levedops. Tole of early treatment and disease progression," Neurology 41(3):380-384  Corne et al., 1999, "Click AMP Res. Demontal. 13(3):328-334  Corne et al., 1999, "Click AMP Res. Demontal. 13(3):328-334  Corral et al., 1999, "Click AMP Res. Demontal. 13(3):328-334  Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl. 1):1107-1113  Clic Craper et al., 1996, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80  Clid Crook et al., 1996, "Neuropsychol. 2:261-276  Francis et al., 1997, "The cohierreigh typothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg, Psychiatry 66(2):137-147  Clis Francis et al., 1997, Medical Neurology, MacMillan Publishing Co., pp. 175-179  Clid Girroy et al., 1997, Medical Neurology, MacMillan Publishing Co., pp. 175-179  Clid Girdoy et al., 1997, Medical Neurology, MacMillan Publishing Co., pp. 175-179  Clid Hawkins et al., 1992, "Comparison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  Levi et al., 1995, "Comparison of acetylcholinesterase determinations	,	C02	disease," Science 295(5556):865-868				
CQ4 Banta et al., 1977, "Elevated manganese levels associated with dementia and extrapyramidal signs," Neurology 27(3):213-216 CO5 Baraitser, 1990, The Genetics of Neurological Disorders, 2" ed., pp. 85-88 CO6 Bourtboudze et al., 2003, "A mouse model of Rubinstein-Tayls layndrome: defective long-term memory is ameliorated by inhibitions of phosphodiesterase 4," Proc. Natl. Acad. Sci. USA, 100(18):10518-10562 CO7 CO7 CO7 CO8	(	C03	tangles in Alzheimer's disease," Brain Res. 477(1-2):90-99				
Baraitser, 1990, The Genetics of Neurological Disorders, 2 <sup>nd</sup> ed., pp. 85-88  Bounchouladze et al., 2003, "A mouse model of Rubinstein-Taybi syndrome defective long-term memory is ameliorated by inhibitors of phosphodiestrase 4, "Proc. Natl. Acad. Sci. USA 100(18):10518-10522  Cor Caine et al., 1987, "Familial Parkinson's disease: possible role of environmental factors," Cara. J. Neurol. Sci. 14(3):303-305  Cos Caraceni et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with levodops: role of early treatment and disease progression," Neurology 41(3):380-384  Cop Casacchia et al., 1983, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," Pharmadol. Res. Commun. 15(3):328-334  Clo Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reliforcement, movement, and affect," J. Comp. Neurol. 407(2):287-301  Corral et al., 1999, "Immunomodulation by halidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl. 1):1107-1113  Clo Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80  Clo Crapper et al., 1989, The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 66(2):137-147  Clo Grid et al., 1989, The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 66(2):137-147  Clo Gifroy et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivastimine," Soc. Neurosci. Abstr. 677-5  Clo Gifroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  Clo Gifroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  Clo Gifroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  Clo Hulley et al., 1999, "Chomparison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416	(	C04	Banta et al., 1977, "Elevated manganese levels associated with dementia and extrapyramidal signs," Neurology				
ameliorated by inhibitors of phosphodiesterase 4." Proc. Natl. Acad. Sci. USA 100(18):10518-10522 C07 Calne et al., 1987, "Familial Parkinson's disease: possible role of environmental factors," Can. J. Neurol. Sci. 14(3):303-305 C08 Caraceni et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with levodops: role of early treatment and disease progression," Neurology 41(3):380-384 C09 Casacchia et al., 1998, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334 C10 Cherry et al., 1999, "Cyclic AMP phosphodiesterase are localized in regions of the mouse brain associated with reinforcement, movement, and affect," J. Comp. Neurol. 407(2):287-301 C11 Corral et al., 1999, "immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl. 1):1107-1113 C12 Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80 C13 Crook et al., 1986, Dev. Neuropsychol. 2:281-276 C14 Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg, Psychiatry 66(2):137-147 C15 Freo et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasimine," Soc. Neurosci. Abstr. 677.5 C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179 C17 Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917 Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Milchel and Ellman Methods," Anal. Chem. 44(2):416-417 C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," Eur. J. Neurosci. 7(12):2431-2440 C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitr	(	C05	Baraitser, 1990, The Genetics of Neurological Disorders, 2 <sup>nd</sup> ed., pp. 85-88				
14(3):303-305  Cascerier et al., 1991, "The occurrence of motor fluctuations in parkinsonian patients treated long term with levodops: role of early treatment and disease progression." Neurology 41(3):380-384  Cosacchia et al., 1998, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334  C10 Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, incorporate and commun. 15(3):329-334  C11 Corral et al., 1999, "Immunomodulation by thaildomide and thaildomide analogues," Ann. Rheum. Dis. 58(Suppl. 1):1107-1113  C12 Crapper et al., 1996, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80  C13 Crook et al., 1998, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 56(2):137-147  C15 Freo et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasitmine," Soc. Neurosci. Abstr. 677.5  C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17 Grundke-lobal et al., 1986, "Ahonormal phosphorylation of the microtubule-associated protein tau (Iau) in Alzheimer ytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Companison of acetycholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," Eur. J. Neurosci. 77(12):2431-2440  C20 Hulley et al., 1996, "Ocyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neural. Transm. Suppl. 46:217-228  C14 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitt et al., 2000, "Neurodegeneration prevented by lentivira		C06					
levodopa: role of early treatment and disease progression," Neurology 41(3):380-384  C09  Casacchia et al., 1983, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334  C10  Chery et al., 1999, "O'Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect," J. Comp. Neurol. 407(2):287-301  C11  Corral et al., 1999, "Immunomodulation by thaildomide and thaildomide analogues," Ann. Rheum. Dis. 58(Suppl.) 1):1107-1113  C12  Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80  C13  Crook et al., 1986, Dev. Neuropsychol. 2:261-276  C14  Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 66(2):137-147  C15  Froe et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasitimine," Soc. Neurosci. Abstr. 677.5  C16  Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17  Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-481.  C19  Hulley et al., 1972, "Companison of acetylcholinesterase determinations by the Milchel and Ellman Methods," Anal. Chem. 44(2):416-417  C19  Hulley et al., 1987, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," Eur. J. Neurosci. 7(12):2431-2440  C20  Hulley et al., 1987, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neurosci. 7(12):2431-2440  C21  Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22  Locy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatr	(	C07	Calne et al., 1987, "Familial Parkinson's disease: possible role of environmental factors," Can. J. Neurol. Sci.				
Casacchia et al., 1983, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease," Pharmacol. Res. Commun. 15(3):329-334  C10 Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect," J. Comp. Neurol. 407(2):287-301  C11 Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl.) 1):1107-1113  C12 Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80  C13 Crook et al., 1986, Dev. Neuropsychol. 2:261-276  C14 Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 66(2):137-147  C15 Freo et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasitmine," Soc. Neurosci. Abstr. 677.5  C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17 Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (Iau) in Alzheimer cytoskeletal pathology, "Proc. Nail. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Comparison of acetylcholinesterase reduce the loxicity of MPTP in substantia nigra neurons in vivo." Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the loxicity of MPTP in substantia nigra neurons in vivo." Eur. J. Neurosci. 7(12):2431-2440  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):999-104  C23 Koris, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent for	(	C08					
C10 Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect," J. Comp. Neurol. 407(2):287-301  C11 Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl.) 1):1107-1113  C12 Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80  C13 Crook et al., 1986, Dev. Neuropsychol. 2:261-276  Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 66(2):137-147  C15 Freo et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasitmine," Soc. Neurosci. Abstr. 677.5  C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17 Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microbule-associated protein lau (lau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Milchel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo." Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+". J. Neural. Transm. Suppl. 46:217-228  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):999-104  C33 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease." Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin	(	C09	Casacchia et al., 1983, "Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in				
C11 Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl.) 1):107-1113  C12 Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80  C13 Crook et al., 1986, Dev. Neuropsychol. 2:261-276  C14 Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 65(2):137-147  C15 Freo et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivastimine," Soc. Neurosci. Abstr. 677.5  C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17 Grundke-Iqbal et al., 1988, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Milchel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+", J. Neural. Transm. Suppl. 46:217-228  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C33 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease." Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline	(	C10	Cherry et al., 1999, "Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with				
C13 Crook et al., 1986, Dev. Neuropsychol. 2:261-276  C14 Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 66(2):137-147  C15 Freo et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasitmine," Soc. Neurosci. Abstr. 677.5  C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17 Grundke-lqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Nall. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo" Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neural. Transm. Suppl. 46:217-228  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Heatth Organization," Int. Psychogeriatr. 6(1):63-88  C27 Luo et al., 2002, "Seuthalamic GAD gene therapy in a Parkinson's disease rat model," S	C	C11	Corral et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58(Suppl.				
C14 Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress," J. Neurol. Neurosurg. Psychiatry 66(2):137-147  C15 Froe et al., 2001, "Effects of Acetycholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasitimine," Soc. Neurosci. Abstr. 677.5  C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17 Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (Iau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo." Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+", J. Neurosi. 7(12):2431-2440  C21 Hyman et al., 1998, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 lacoviti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2000, "Sci. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6" ed., Lea & Febiger, Philadelphia, pp. 484-489  Mufson et al	(	C12	Crapper et al., 1976, "Aluminium, neurofibrillary degeneration and Alzheimer's disease," Brain 99(1):67-80				
Neurosurg, Psychiatry 66(2):137-147  C15 Froe et al., 2001, "Effects of Acetypholinesterase inhibition in mild cognitive impairment (MCI): Preliminary results with Rivasitmine," Soc. Neurosci. Abstr. 677.5  C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17 Grundke-liqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterase edeterminations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neural. Transm. Suppl. 46:217-282  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Heath Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-	(	C13	Crook et al., 1986, Dev. Neuropsychol. 2:261-276				
with Rivasitmine," Soc. Neurosci. Abstr. 677.5  C16 Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179  C17 Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+", J. Neurol. Transm. Suppl. 46:217-228  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  McGeer et al., 2001, "B.C. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6" ed., Lea & Febiger, Philadelphia, pp. 484-489  Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490	(	C14					
C17 Grundke-Iqbal et al., 1986, "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972, "Comparison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo." Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neural. Transm. Suppl. 46:217-228  C21 Hyman et al., 1998, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacoviti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  McGeer et al., 2001, Ec. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489  Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490	(	C15					
cytoskeletal pathology." Proc. Natl. Acad. Sci. USA 83(13):4913-4917  C18 Hawkins et al., 1972. "Companison of acetylcholinesterase determinations by the Michel and Ellman Methods," Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo," Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neurol. Transm. Suppl. 46:217-228  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Leve et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Heath Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  McGeer et al., 2001, "B.C. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6" ed., Lea & Febiger, Philadelphia, pp. 484-489  Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490  Mufson et al., 1999, "Amino-substituted thalidomide analogs; potent inhibitors of TNF-alpha production," Bioorg.	(	C16	Gilroy et al., 1979, Medical Neurology, MacMillan Publishing Co., pp. 175-179				
Anal. Chem. 44(2):416-417  C19 Hulley et al., 1995, "Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo." Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cycle AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+". J. Neural. Transm. Suppl. 46:217-228  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  C28 Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197  C29 McGeer et al., 2001, Bc. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489  Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490  Mufson et al., 1999, "Amino-substituted thalidomide analogs; potent inhibitors of TNF-alpha production," Bioorg.		C17					
neurons in vivo." Eur. J. Neurosci. 7(12):2431-2440  C20 Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neural. Transm. Suppl. 46:217-228  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2000, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Asoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  C28 Maher et al., 2002, "Subthalamic GAD gene therapy in a Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197  C29 McGeer et al., 2001, Ec. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489  Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490  C32 Mufler et al., 1999, "Amino-substituted thalidomide analogs; potent inhibitors of TNF-alpha production," Bioorg.		C18	Anal. Chem. 44(2):416-417				
toxic effects of MPP+,"J. Neural. Transm. Suppl. 46:217-228  C21 Hyman et al., 1988, "Alz-50 antibody recognizes Alzheimer-related neuronal changes," Ann. Neurol. 23(4):371-379  C22 Iacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104  C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  C28 Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197  C29 McGeer et al., 2001, B.C. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489  C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490  C32 Muller et al., 1999, "Amino-substituted thalidomide analogs; potent inhibitors of TNF-alpha production," Bioorg.		C19	neurons in vivo," Eur. J. Neurosci. 7(12):2431-2440				
C22 lacovitti et al., 2001, "Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line," Brain Res. 912(1):99-104 C23 Kordworer et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773 C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104 C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260 C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68 C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429 C28 Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197 C29 McGeer et al., 2001, B.C. Med. J. 43:138-141 C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490 C32 Mulfer et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490	(	C20	Hulley et al., 1995, "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+," J. Neural. Transm. Suppl. 46:217-228				
Brain Res. 912(1):99-104 C23 Kordower et al., 2000, "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease," Science 290(5492):767-773 C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104 C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260 C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68 C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model." Science 298(5592):425-429 C28 Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197 C29 McGeer et al., 2001, B.C. Med. J. 43:138-141 C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489 C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490 C32 Muller et al., 1999, "Amino-substituted thalidomide analogs; potent inhibitors of TNF-alpha production," Bioorg.		C21					
Parkinson's disease, "Science 290(5492):767-773  C24 Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104  C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  C28 Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197  C29 McGeer et al., 2001, B.C. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489  C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490  C32 Muller et al., 1999, "Amino-substituted thalidomide analogs; potent inhibitors of TNF-alpha production," Bioorg.		C22	Brain Res. 912(1):99-104				
C25 Kral, 1962, "Senescent forgetfulness: benign and malignant," Can. Med. Assoc. J. 86:257-260  C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeniatr. 6(1):63-68  C27 Luce t al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  C28 Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197  C29 McGeer et al., 2001, B.C. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6" ed., Lea & Febiger, Philadelphia, pp. 484-489  C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490  C32 Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg.		C23					
C26 Levy et al., 1994, "Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Lue et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  C28 Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197  C29 McGeer et al., 2001, B.C. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6" ed., Lea & Febiger, Philadelphia, pp. 484-489  C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490  C32 Muller et al., 1999, "Amino-substituted thalidomide analogs; potent inhibitors of TNF-alpha production," Bioorg.	(	C24	Kosik, 1990, "Tau protein and Alzheimer's disease," Curr. Opin. Cell. Biol. 2(1):101-104				
Association in collaboration with the World Health Organization," Int. Psychogeriatr. 6(1):63-68  C27 Luo et al., 2002, "Subthalamic GAD gene therapy in a Parkinson's disease rat model," Science 298(5592):425-429  Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197  C29 McGeer et al., 2001, B.C. Med. J. 43:138-141  C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489  C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490  C32 Muller et al., 1999, "Amino-substituted thalidomide analogs; potent inhibitors of TNF-alpha production," Bioorg.	(	C25					
C28 Maher et al., 2002, "Segregation analysis of Parkinson disease revealing evidence for a major causative gene," Am. J. Med. Genet. 109(3):191-197 C29 McGeer et al., 2001, B.C. Med. J. 43:138-141 C30 Merritt, 1979, A Textbook of Neurol., 6" ed., Lea & Febiger, Philadelphia, pp. 484-489 C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490 C32 Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg.		C26					
Am. J. Med. Genet. 109(3):191-197 C29 McGeer et al., 2001, B.C. Med. J. 43:138-141 C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489 C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):459-490 C32 Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg.	(	C27					
C30 Merritt, 1979, A Textbook of Neurol., 6 <sup>th</sup> ed., Lea & Febiger, Philadelphia, pp. 484-489  C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):459-490  C32 Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg.		C28					
C31 Mufson et al., 1999, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment," Exp. Neurol. 158(2):469-490 C32 Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg.		C29					
Neurol. 158(2):469-490  C32 Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg.		C30					
		C31	Neurol. 158(2):469-490				
		C32					

Sheet 4 of 4

	C33	Nussbaum et al., 1997, "Genetics of Parkinson's disease," Hum. Mol. Genet. 6(10):1687-1691				
	C34	Olson, 2000, "Biomedicine. Combating Parkinson's diseasestep three," Science 290(5492):721-724				
	C35	Parkes et al., 1984, "Rolipram in Parkinson's disease," Adv. Neurol. 40:563-565				
	C36	Petersen et al., 2001, "Current concepts in mild cognitive impairment," Arch. Neurol. 58(12):1985-1992				
	C37	Petersen et al., 1999, "Mild cognitive impairment: clinical characterization and outcome," Arch. Neurol. 56(3):303-308				
	C38	Petersen et al., 1995, "Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals," JAMA 273(16):1274-1278				
	C39	Polymeropoulos et al., 1996, "Mapping of a gene for Parkinson's disease to chromosome 4q21-q23," Science 274(5290):1197-1199				
•	C40	Price et al., 1999, "Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease," Ann. Neurol. 45(3):358-368				
	C41	Rabe et al., 1982, "Enhancement of depolarization-dependent neurosecretion from PC12 cells by forskolin-induced elevation of cyclic AMP," J. Cyclic. Nucleotide Res. 8(6):371-384				
	C42	Rousselet et al., 2002, "Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP," Exp. Neurol. 177(1):183-192				
	C43	Sriram et al., 2002, "Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease," FASEB J. 16(11):1474-1476 Takahashi et al., 1999, "Chronic antidepressant administration increases the expression of cAMP-specific				
	C44	Takahashi et al., 1999, "Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms," J. Neurosci. 19(2):610-618				
	C45	Traynor et al., 1984, "Phospholipases elevate cyclic AMP levels and promote neunte extension in a clonal nerve cell line," Dev. Brain Res. 316(2):197-204				
	C46	Troncoso et al., 1996, "Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging," Neurobiol. Aging 17(3):365-371				
	C49	Westlund et al., 1992, "Effects of nerve growth factor and acetyl-L-carnitine arginyl amide on the human neuronal line HCN-1A," Int. J. Dev. Neurosci. 10(5):361-373				
	C48	Wolff, ed., 1995, I Burger's Medicinal Chemistry and Drug Discovery, 5 <sup>th</sup> ed., pp. 172-178 and 949-982				
	C49	Wolozin et al., 1987, "Alzheimer-related neuronal protein A68: specificity and distribution," Ann. Neurol. 22(4):521-526				
	C53	Zhu et al., 2001, "The antidepressant and antiinflammatory effects of rolipram in the central nervous system," CNS Drug Rev. 7(4):387-398				
	C51	Engelhart et al., 2002, "Dietary intake of antioxidants and risk of Alzheimer Disease," J. Am. Med. Assoc. 287(24):3223-3229				
	C52	Foley et al., 2002, "Dietary intake of antioxidants and risk of Alzheimer Disease," J. Am. Med. Assoc. 287(24):3261-3263				
	C53	Morris et al., 2002, "Dietary intake of antioxidant nutrients and the risk of incident Alzheimer Disease in a biracial community study," J. Am. Med. Assoc. 287(24):3230-3237				
	C54	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition," Bioorg. Med. Chem. Lett. 8(19):2669-2674				
	C55	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," J. Med. Chem. 39(17):3238-3240				
	C56	Physician's Desk Reference, 2002, 56 <sup>th</sup> ed., pp. 1755-1760				
	C57	Saha et al., 2003, "Tumor necrosis factor-a at the crossroads of neuronal life and death during HIV-associated dementia," J. Neurochem. 86:1057-1071				
	C58	Wolff ed., 1995, Burger's Medicinal Chemistry and Drug Discovery, 5 <sup>th</sup> ed. 172-178, 949-982				
	C59	DREDGE et al., 2003, "Angiogenesis inhibitors in cancer therapy," Curr. Opin. Investig. Drugs 4(6):667-673				
	C60	DREDGE et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," Crit. Rev. Immunol. 22(5-6):425-437				
	C51	DREDGE et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," Br. J. Cancer 87(10):1166-1172				
	C62	DREDGE et al., 2002, "Recent developments in antiangiogenic therapy," Expert Opin. Biol. Ther. 2(8):953-966				
	C53	GEE et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," Cancer Res. 63(23):8073-8078				
	C53	MARRIOTT et al., 2001, "Immunotherapeutic and antitumour potential of thalidomide analogues," Expert Opin. Biol. Ther. 1(4):1-8				
	C65	MARRIOTT et al., 2002, "Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells," Clin. Exp. Immunol. 130(1):75-84				
	C66	MOLOGOPHON I ARRANGO CONTRACTOR C				
	C67					
EXAMINER		DATE CONSIDERED				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.